Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.

Leukemia - 1 Jul 2007

Guillem V M, Collado M, Terol M J, Calasanz M J, Esteve J, Gonzalez M, Sanzo C, Nomdedeu J, Bolufer P, Lluch A, Tormo M

Abstract excerpt

Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a malignancy occurring after exposure to chemotherapy and/or radiotherapy. Polymorphisms involved in chemotherapy/radiotherapy response genes could be related to an increased risk of developing this neoplasia. We have studied 11 polymorphisms in genes of drug detoxification pathways (NQO1, glutathione S-transferase pi) and DNA repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Haplotypes

Share to Hematologic Neoplasms

Share to Leukemia

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Neoplasms, Second Primary

Source

Identifiers

PMID: 17476281
DOI: 10.1038/sj.leu.2404709

Genes

MTHFR
NQO1
XPC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.PMID 17476281Read ↗

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.Semantic proximity Read ↗

Influence of DNA damage and repair upon the risk of treatment related leukemia.Semantic proximity Read ↗

Genetic predisposition and treatment-related leukemia.Semantic proximity Read ↗

Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.Semantic proximity Read ↗

[Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].Semantic proximity Read ↗

[Risk of cancer and malignant transformation in hematology practice].Semantic proximity Read ↗

The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.Semantic proximity Read ↗

Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression.Semantic proximity Read ↗

Detoxification and DNA repair genes polymorphisms and susceptibility of primary myelodysplastic syndromes in Chinese population.Semantic proximity Read ↗

Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes.Semantic proximity Read ↗

DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.